Neoadjuvant chemotherapy may improve outcomes among patients with resectable pancreatic ductal adenocarcinoma, according to a study published in The Lancet Gastroenterology & Hepatology.
The standard of care for patients with pancreatic adenocarcinoma is surgical resection followed by adjuvant combination chemotherapy, but the addition of preoperative chemotherapy may eradicate micrometastatic disease and direct postoperative therapy in the case of resistance. Read more . . .